ScholarIQanswers from OpenAlex & ORCID
Richard G. Wunderink
ResearcherPublications, citations & collaboration network
Richard G. Wunderink is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard G. Wunderink have?
ScholarIQindexed works
Richard G. Wunderink has 593 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard G. Wunderink have?
ScholarIQcitation count
Richard G. Wunderink has 48,576 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard G. Wunderink?
ScholarIQh-index
Richard G. Wunderink has an h-index of 99 in OpenAlex.
What is the i10-index of Richard G. Wunderink?
ScholarIQi10-index
Richard G. Wunderink has an i10-index of 302 in OpenAlex.
What is the ORCID of Richard G. Wunderink?
ScholarIQorcid
The ORCID for Richard G. Wunderink is on the source record.
What is the OpenAlex record for Richard G. Wunderink?
ScholarIQopenalex
The OpenAlex for Richard G. Wunderink is on the source record.
What are the most-cited papers on Richard G. Wunderink?
ScholarIQmost cited works
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
Antoní Torres, Michael S. Niederman, Jean Chastre, Santiago Ewig, Patricia Fernandez-Vandellos, Håkan Hanberger, Marin H. Kollef, Gianluigi Li Bassi, Carlos M. Luna, Ignacio Martín‐Loeches, José Artur Paiva, Robert C. Read, David Rigau, Jean‐François Timsit, Tobias Welte, Richard G. Wunderink
Angiotensin II for the Treatment of Vasodilatory Shock
Ashish K. Khanna, Shane English, Xueyuan S. Wang, Kealy R. Ham, James A. Tumlin, Harold M. Szerlip, Laurence W. Busse, Laith Altaweel, Timothy E. Albertson, Caleb Mackey, Michael T. McCurdy, David W. Boldt, Stefan Chock, Paul J. Young, Kenneth Krell, Richard G. Wunderink, Marlies Ostermann, Raghavan Murugan, Michelle N. Gong, Rakshit Panwar, Johanna Hästbacka, Raphaël Favory, Balasubramanian Venkatesh, Bruce Thompson, Rinaldo Bellomo, Jeffrey Jensen, Stew Kroll, Lakhmir S. Chawla, George F. Tidmarsh, Adam M. Deane
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti, Roger Echols, Yuko Matsunaga, Mari Ariyasu, Yohei Doi, Ricard Ferrer, Thomas P. Lodise, Thierry Naas, Yoshihito Niki, David L. Paterson, Simon Portsmouth, Julián Torre‐Cisneros, Kiichiro Toyoizumi, Richard G. Wunderink, Tsutae Den Nagata
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Richard G. Wunderink, Jordi Rello, Sue Cammarata, Rodney Croos‐Dabrera, Marin H. Kollef
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu, Philippe Clevenbergh, Roger Echols, Keith S. Kaye, Marin H. Kollef, Anju Menon, Jason M. Pogue, Andrew F. Shorr, Jean‐François Timsit, Markus Zeitlinger, Tsutae Den Nagata